Precision BioSciences, Inc. (DTIL) |
|
0.7536 0.052 (7.35%)
|
03-31 16:00 |
|
Open: |
0.718 |
Pre. Close: |
0.702 |
|
High:
|
0.76 |
Low:
|
0.7005 |
|
Volume:
|
708,860 |
Market Cap:
|
84(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:09 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.17 One year: 1.4 |
| Support: |
Support1: 0.68 Support2: 0.56 |
| Resistance: |
Resistance1: 1 Resistance2: 1.2 |
| Pivot: |
0.8  |
| Moving Average: |
MA(5): 0.74 MA(20): 0.86
MA(100): 1.16 MA(250): 1.46 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 14.4 %D(3): 13.7 |
| RSI: |
RSI(14): 35.6 |
| 52-week: |
High: 3.08 Low: 0.68 |
| Average Vol(K): |
3-Month: 635 (K) 10-Days: 935 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DTIL ] has closed above bottom band by 31.9%. Bollinger Bands are 11.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.78 - 0.79 |
0.79 - 0.79 |
|
Low:
|
0.69 - 0.7 |
0.7 - 0.7 |
|
Close:
|
0.7 - 0.7 |
0.7 - 0.71 |
|
Company Description |
|
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. |
Headline News |
Mon, 27 Mar 2023
Precision BioSciences to Participate in Upcoming Guggenheim ... - Business Wire
Sun, 26 Mar 2023
European Commission Grants Orphan Designation for iECURE's ... - Manchestertimes
Tue, 14 Mar 2023
Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way? - Simply Wall St
Thu, 09 Mar 2023
Precision BioSciences: Q4 Earnings Snapshot - The Herald Review
Thu, 09 Mar 2023
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 ... - Business Wire
Sun, 05 Mar 2023
Precision BioSciences (DTIL) to Release Earnings on Thursday - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
111 (M) |
| Shares Float |
79 (M) |
|
% Held by Insiders
|
17 (%) |
|
% Held by Institutions
|
51 (%) |
|
Shares Short
|
779 (K) |
|
Shares Short P.Month
|
754 (K) |
Stock Financials |
|
EPS
|
-1.25 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.55 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-399.9 |
|
Return on Assets (ttm)
|
-27.9 |
|
Return on Equity (ttm)
|
-147.3 |
|
Qtrly Rev. Growth
|
67.1 |
|
Gross Profit (p.s.)
|
0.22 |
|
Sales Per Share
|
0.22 |
|
EBITDA (p.s.)
|
-0.84 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-46 (M) |
|
Levered Free Cash Flow
|
-7 (M) |
Stock Valuations |
|
PE Ratio
|
-0.61 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.37 |
|
Price to Sales
|
3.34 |
|
Price to Cash Flow
|
-1.84 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
